missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human Cystatin B (aa 1-22) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (86%), Rat (86%). This recombinant protein control fragment may be used for blocking experiments. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Cystatin A (also designated STF1, STFA, stefin A or cystatin AS) and cystatin B (also designated PME, CST6, STFB, CPI-B, stefin B and liver thiol proteinase inhibitor) are thiol protease inhibitors that form complexes with Papain and the cathepsins B, H and L. Cystatin A, a cytoplasmic protein, is one of the precursor proteins of the cornified cell envelope in keratinocytes and plays a role in epidermal development and maintenance. Cystatin B protects against intracellular proteases leaking out of lysosomes and is primarily expressed in heart, liver and kidney.
Specifications
Specifications
| Accession Number | P04080 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 1476 |
| Name | Human Cystatin B (aa 1-22) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | AA960480; CPI-B; Cst6; CSTB; Cyb; cystatin B; cystatin B (stefin B); cystatin B protein; cystatin beta; cystatin-B; Cystatin-beta; Epm1; EPM1A; Liver thiol proteinase inhibitor; LOC101123010; PME; stefin B; Stefin-B; stefin-C; Stfb; ULD; Unknown (protein for MGC:134609) |
| Common Name | Cystatin B |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction